Latest Period
Q1 2026
Security Snapshot
BIOCRYST PHARMACEUTICALS INC - COMMON STOCK (BCRX) Institutional Ownership
CUSIP: 09058V103
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
298
Shares (Excl. Options)
247,442,463
Price
$9.52
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- BCRX on Nasdaq
- Shares outstanding
- 249,150,204
- Price per share
- $8.99
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 247,442,463
- Total reported value
- $2,355,312,270
- % of total 13F portfolios
- 0%
- Share change
- +34,253,562
- Value change
- +$351,468,980
- Number of holders
- 298
- Price from insider filings
- $8.99
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- BCRX - BIOCRYST PHARMACEUTICALS INC - COMMON STOCK is tracked under CUSIP 09058V103.
- 298 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 274 to 298 between Q4 2025 and Q1 2026.
- Reported value moved from $1,657,283,429 to $2,355,312,270.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 298 institutions filings for Q1 2026.
Security key
09058V103
Latest holder period
Q1 2026
13F holders
298
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
BCRX full holder history
BIOCRYST PHARMACEUTICALS INC SEC filings
BIOCRYST PHARMACEUTICALS INC company facts
BIOCRYST PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 09058V103:
Significant Owners of BIOCRYST PHARMACEUTICALS INC - COMMON STOCK (BCRX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 8.4% | $143,714,288 | 17,483,490 | BlackRock, Inc. | 31 Mar 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 7.3% | $116,143,592 | 15,302,186 | RA Capital Management, L.P. | 04 Nov 2025 | |||
| Flynn James E | 6.8% | +17% | $109,278,420 | +$16,550,640 | 14,341,000 | +18% | Deerfield Mgmt, L.P. | 31 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $123,390,357 | 12,961,172 | Vanguard Capital Management | 31 Mar 2026 | |||
| STATE STREET CORP | 4.9% | -8% | $114,880,668 | +$10,681,752 | 12,208,360 | +10% | STATE STREET CORPORATION | 31 Mar 2026 |
| Avoro Capital Advisors LLC | 4.2% | $71,514,000 | 8,700,000 | Avoro Capital Advisors LLC | 31 Mar 2025 |
As of 31 Mar 2026, 298 institutional investors reported holding 247,442,463 shares of BIOCRYST PHARMACEUTICALS INC - COMMON STOCK (BCRX). This represents 99% of the company’s total 249,150,204 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of BIOCRYST PHARMACEUTICALS INC - COMMON STOCK (BCRX) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9.1% | 22,650,988 | +7.2% | 0% | $215,637,401 |
| RA CAPITAL MANAGEMENT, L.P. | 6.4% | 15,827,186 | 0% | 1.6% | $150,674,811 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 6% | 15,038,000 | +4.9% | 1.7% | $143,161,760 |
| STATE STREET CORP | 4.9% | 12,208,360 | +10% | 0% | $116,223,587 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5% | 11,244,625 | 0% | 0.01% | $107,048,830 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 11,135,762 | 0% | 0% | $106,012,454 |
| TCG Crossover Management, LLC | 4.4% | 11,020,968 | 3% | $104,919,615 | |
| JANUS HENDERSON GROUP PLC | 3.6% | 8,908,506 | +20% | 0.04% | $84,853,520 |
| PERCEPTIVE ADVISORS LLC | 3% | 7,434,033 | +135% | 1.4% | $70,771,994 |
| Vestal Point Capital, LP | 2.8% | 7,025,000 | +212% | 1.9% | $66,878,000 |
| TWO SIGMA INVESTMENTS, LP | 2.6% | 6,392,628 | +42% | 0.05% | $60,857,819 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 5,782,776 | +14% | 0% | $55,063,276 |
| Kynam Capital Management, LP | 2.3% | 5,680,795 | -39% | 3.4% | $54,081,168 |
| BANK OF AMERICA CORP /DE/ | 2% | 5,091,765 | +232% | 0% | $48,473,603 |
| Aberdeen Group plc | 2% | 5,040,670 | +452% | 0.08% | $47,987,178 |
| UBS Group AG | 2% | 4,943,994 | -6.1% | 0.01% | $47,066,823 |
| Frazier Life Sciences Management, L.P. | 1.6% | 4,009,240 | 0.98% | $38,167,965 | |
| Royalty Pharma Sub-Manager, LLC | 1.5% | 3,846,154 | 0% | 21% | $36,615,386 |
| Nuveen, LLC | 1.5% | 3,819,263 | +5.7% | 0.01% | $36,359,384 |
| GW&K Investment Management, LLC | 1.3% | 3,240,462 | +2.5% | 0.27% | $30,850,000 |
| Eversept Partners, LP | 1.2% | 3,039,820 | +1.6% | 1.9% | $28,939,086 |
| RFG Advisory, LLC | 1.2% | 2,870,700 | 0.5% | $27,329,064 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.1% | 2,815,304 | +319% | 0.03% | $26,801,694 |
| Fisher Asset Management, LLC | 1.1% | 2,733,253 | +11% | 0.01% | $26,020,567 |
| DIMENSIONAL FUND ADVISORS LP | 1.1% | 2,690,651 | +119% | 0.01% | $25,614,944 |
Institutional Holders of BIOCRYST PHARMACEUTICALS INC - COMMON STOCK (BCRX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 247,442,463 | $2,355,312,270 | +$351,468,980 | $9.52 | 298 |
| 2025 Q4 | 212,542,303 | $1,657,283,429 | +$104,832,674 | $7.80 | 274 |
| 2025 Q3 | 194,102,191 | $1,473,118,671 | -$35,936,486 | $7.59 | 282 |
| 2025 Q2 | 197,129,798 | $1,766,723,682 | +$203,493,373 | $8.96 | 292 |
| 2025 Q1 | 174,435,511 | $1,308,746,834 | +$63,398,447 | $7.50 | 273 |
| 2024 Q4 | 167,662,220 | $1,261,171,584 | -$40,361,715 | $7.52 | 256 |
| 2024 Q3 | 173,102,982 | $1,315,577,234 | -$13,496,556 | $7.60 | 255 |
| 2024 Q2 | 174,343,886 | $1,077,260,403 | -$26,171,848 | $6.18 | 238 |
| 2024 Q1 | 179,854,267 | $913,665,406 | +$14,530,963 | $5.08 | 235 |
| 2023 Q4 | 176,879,832 | $1,059,530,995 | -$13,874,803 | $5.99 | 234 |
| 2023 Q3 | 175,748,697 | $1,244,274,073 | +$20,781,164 | $7.08 | 229 |
| 2023 Q2 | 174,092,743 | $1,225,943,210 | +$15,794,543 | $7.04 | 233 |
| 2023 Q1 | 170,682,621 | $1,423,483,184 | +$98,954,044 | $8.34 | 237 |
| 2022 Q4 | 157,670,070 | $1,809,819,957 | +$89,114,288 | $11.48 | 225 |
| 2022 Q3 | 149,200,472 | $1,879,908,994 | -$39,491,355 | $12.60 | 218 |
| 2022 Q2 | 151,882,406 | $1,606,941,793 | +$202,016,904 | $10.58 | 207 |
| 2022 Q1 | 127,644,333 | $2,074,127,946 | +$162,394,498 | $16.26 | 219 |
| 2021 Q4 | 118,034,837 | $1,624,605,826 | +$189,498,647 | $13.85 | 197 |
| 2021 Q3 | 103,285,294 | $1,484,281,647 | -$23,674,937 | $14.37 | 191 |
| 2021 Q2 | 104,615,646 | $1,653,902,810 | +$25,597,252 | $15.81 | 190 |
| 2021 Q1 | 104,536,942 | $1,063,154,138 | -$141,911,795 | $10.17 | 183 |
| 2020 Q4 | 120,536,116 | $897,922,105 | -$43,570,187 | $7.45 | 172 |
| 2020 Q3 | 127,504,811 | $438,191,012 | -$23,494,376 | $3.44 | 150 |
| 2020 Q2 | 133,168,915 | $634,861,180 | +$96,615,986 | $4.76 | 160 |
| 2020 Q1 | 122,545,605 | $245,076,906 | -$37,929,778 | $2.00 | 127 |
| 2019 Q4 | 137,257,236 | $473,298,973 | +$126,158,746 | $3.45 | 131 |
| 2019 Q3 | 98,732,839 | $282,887,178 | -$6,967,337 | $2.86 | 110 |
| 2019 Q2 | 100,189,285 | $379,651,222 | -$87,862,478 | $3.79 | 112 |
| 2019 Q1 | 101,459,192 | $825,845,210 | +$1,493,806 | $8.14 | 129 |
| 2018 Q4 | 101,241,798 | $817,039,643 | +$8,890,495 | $8.07 | 118 |
| 2018 Q3 | 100,143,382 | $764,063,804 | +$73,654,467 | $7.63 | 110 |
| 2018 Q2 | 87,486,065 | $501,300,833 | -$8,812,924 | $5.73 | 98 |
| 2018 Q1 | 89,084,172 | $424,940,474 | -$6,631,982 | $4.77 | 98 |
| 2017 Q4 | 90,315,627 | $443,489,038 | +$30,241,042 | $4.91 | 111 |
| 2017 Q3 | 83,706,610 | $438,584,580 | +$76,310,817 | $5.24 | 118 |
| 2017 Q2 | 69,068,637 | $384,022,057 | +$3,627,924 | $5.56 | 112 |
| 2017 Q1 | 67,625,892 | $568,043,111 | +$140,009,973 | $8.40 | 114 |
| 2016 Q4 | 58,390,925 | $369,592,679 | +$11,848,602 | $6.33 | 107 |
| 2016 Q3 | 56,560,503 | $249,434,126 | +$23,437,473 | $4.41 | 98 |
| 2016 Q2 | 51,754,204 | $146,980,142 | -$10,557,522 | $2.84 | 91 |
| 2016 Q1 | 55,499,247 | $157,041,490 | -$57,851,659 | $2.83 | 103 |
| 2015 Q4 | 63,010,560 | $650,239,667 | -$21,193,454 | $10.32 | 116 |
| 2015 Q3 | 64,961,257 | $740,441,332 | +$18,203,435 | $11.40 | 123 |
| 2015 Q2 | 62,979,534 | $940,208,410 | -$26,293,353 | $14.93 | 121 |
| 2015 Q1 | 64,945,642 | $586,470,031 | +$36,664,370 | $9.03 | 96 |
| 2014 Q4 | 60,839,929 | $739,630,154 | +$22,530,982 | $12.16 | 90 |
| 2014 Q3 | 56,671,419 | $554,271,573 | +$30,624,768 | $9.78 | 101 |
| 2014 Q2 | 53,076,615 | $676,805,598 | +$130,669,664 | $12.75 | 100 |
| 2014 Q1 | 43,477,699 | $460,383,679 | +$93,247,685 | $10.58 | 86 |